AASLD 2015

Treatment with tenofovir disoproxil fumarate in late pregnancy in highly viremic mothers with hepatitis B virus (HBV) infection effectively reduced mother-to-child transmission, a study reported at The Liver Meeting® 2015.

Monotherapy with tenofovir disoproxil fumarate (TDF) was equally effective as combination therapy with emtricitabine/TDF (FTC/TDF) in patients with chronic hepatitis B virus (HBV) infection harboring lamivudine resistance mutations, a study presented at The Liver Meeting® 2015 has found.

Antiviral therapy in patients with non-cirrhotic chronic hepatitis B (CHB) and normal to minimally-elevated alanine aminotransferase (ALT) levels significantly reduced the risk of hepatocellular carcinoma, reported Joseph K. Hoang from Stanford University Medical Center, Palo Alto, CA, at The Liver Meeting® 2015.

A rapid decline in serum/plasma lysyl oxidase-like-2 (LOXL2) levels was seen in cirrhotic patients treated with sofosbuvir (SOF)-based therapy, reported authors of a new study presented at The Liver Meting® 2015.

New data reported at The Liver Meeting® 2015 indicate that entecavir monotherapy without hepatitis B immune globulin (HBIG) effectively prevents graft loss and death from recurrent hepatitis B after liver transplantation in patients with chronic hepatitis B without prior drug resistant mutations.

Drinking coffee might reduce the risk of alcoholic hepatitis (AH) among heavy alcohol drinkers, according to a study reported at The Liver Meeting® 2015

Early biomarkers cystatin C and NGAL may facilitate the safe delivery of long-term nucleos(t)ide analogue (NA) therapy for patients who have undergone liver transplantation, according to a study reported at the The Liver Meeting® 2015.

Aspirin and clopidogrel therapy are associated with reduced risk of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B infection, according to a study reported at the The Liver Meeting® 2015.

The combination of two next-generation direct-acting antiviral (DAA) agents, ABT-493 and ABT-530, was “well tolerated,” with all non-cirrhotic patients with hepatitis C virus (HCV) genotype 1 (GT1) infection who completed the 8-week treatment period achieving sustained virologic response at 12 weeks (SVR12), a study presented at The Liver Meeting 2015® has found.